Ana Paula Candiota

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3124870/publications.pdf

Version: 2024-02-01

46 papers	778 citations	471371 17 h-index	552653 26 g-index
46 all docs	46 docs citations	46 times ranked	1311 citing authors

#	Article	IF	Citations
1	Synthesis and Validation of a Bioinspired Catechol-Functionalized Pt(IV) Prodrug for Preclinical Intranasal Glioblastoma Treatment. Cancers, 2022, 14, 410.	1.7	9
2	Establishing Imaging Biomarkers of Host Immune System Efficacy during Glioblastoma Therapy Response: Challenges, Obstacles and Future Perspectives. Metabolites, 2022, 12, 243.	1.3	2
3	Intranasal Administration of Catechol-Based Pt(IV) Coordination Polymer Nanoparticles for Glioblastoma Therapy. Nanomaterials, 2022, 12, 1221.	1.9	4
4	Metal-Free Radical Dendrimers as MRI Contrast Agents for Glioblastoma Diagnosis: Ex Vivo and In Vivo Approaches. Biomacromolecules, 2022, 23, 2767-2777.	2.6	10
5	Successful Partnerships: Exploring the Potential of Immunogenic Signals Triggered by TMZ, CX-4945, and Combined Treatment in GL261 Glioblastoma Cells. International Journal of Molecular Sciences, 2021, 22, 3453.	1.8	7
6	Conservation of Aging and Cancer Epigenetic Signatures across Human and Mouse. Molecular Biology and Evolution, 2021, 38, 3415-3435.	3.5	5
7	Bioinspired Theranostic Coordination Polymer Nanoparticles for Intranasal Dopamine Replacement in Parkinsonâ€™s Disease. ACS Nano, 2021, 15, 8592-8609.	7.3	50
8	Immune System-Related Changes in Preclinical GL261 Glioblastoma under TMZ Treatment: Explaining MRSI-Based Nosological Imaging Findings with RT-PCR Analyses. Cancers, 2021, 13, 2663.	1.7	7
9	Antiâ€tumour immune response in GL261 glioblastoma generated by Temozolomide Immuneâ€Enhancing Metronomic Schedule monitored with MRSIâ€based nosological images. NMR in Biomedicine, 2020, 33, e4229.	1.6	15
10	Anti-PD-1 Immunotherapy in Preclinical GL261 Glioblastoma: Influence of Therapeutic Parameters and Non-Invasive Response Biomarker Assessment with MRSI-Based Approaches. International Journal of Molecular Sciences, 2020, 21, 8775.	1.8	14
11	Unraveling response to temozolomide in preclinical GL261 glioblastoma with MRI/MRSI using radiomics and signal source extraction. Scientific Reports, 2020, 10, 19699.	1.6	7
12	Interpreting response to TMZ therapy in murine GL261 glioblastoma by combining Radiomics, Convex-NMF and feature selection in MRI/MRSI data analysis. , 2020, , .		0
13	Robust Conditional Independence maps of single-voxel Magnetic Resonance Spectra to elucidate associations between brain tumours and metabolites. PLoS ONE, 2020, 15, e0235057.	1.1	2
14	Embedding MRI information into MRSI data source extraction improves brain tumour delineation in animal models. PLoS ONE, 2019, 14, e0220809.	1.1	3
15	Up-Regulation of the Alpha Prime Subunit of Protein Kinase CK2 as a Marker of Fast Proliferation in GL261 Cultured Cells. Pathology and Oncology Research, 2019, 25, 1659-1663.	0.9	6
16	Cancer metabolism in a snapshot: MRS(I). NMR in Biomedicine, 2019, 32, e4054.	1.6	17
17	Dual T₁/T₂ Nanoscale Coordination Polymers as Novel Contrast Agents for MRI: A Preclinical Study for Brain Tumor. ACS Applied Materials & Interfaces, 2018, 10, 38819-38832.	4.0	50
18	Metronomic treatment in immunocompetent preclinical GL261 glioblastoma: effects of cyclophosphamide and temozolomide. NMR in Biomedicine, 2017, 30, e3748.	1.6	23

#	Article	IF	Citations
19	Brain metabolic pattern analysis using a magnetic resonance spectra classification software in experimental stroke. BMC Neuroscience, 2017, 18, 13.	0.8	5
20	Metabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide Treatment. Metabolites, 2017, 7, 20.	1.3	19
21	Targeting Protein Kinase CK2: Evaluating CX-4945 Potential for GL261 Glioblastoma Therapy in Immunocompetent Mice. Pharmaceuticals, 2017, 10, 24.	1.7	30
22	Development of a transplantable glioma tumour model from genetically engineered mice: MRI/MRS/MRSI characterisation. Journal of Neuro-Oncology, 2016, 129, 67-76.	1.4	5
23	MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis. NMR in Biomedicine, 2016, 29, 732-743.	1.6	19
24	Protein Kinase CK2 Content in GL261 Mouse Glioblastoma. Pathology and Oncology Research, 2016, 22, 633-637.	0.9	5
25	Improving Ribosomal RNA Integrity in Surgically Resected Human Brain Tumor Biopsies. Biopreservation and Biobanking, 2016, 14, 156-164.	0.5	6
26	r1andr2Relaxivities of Dendrons Based on a OEG-DTPA Architecture: Effect of Gd3+Placement and Dendron Functionalization. Journal of Nanotechnology, 2015, 2015, 1-8.	1.5	2
27	In Vivo and Ex Vivo Magnetic Resonance Spectroscopy of the Infarct and the Subventricular Zone in Experimental Stroke. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 828-834.	2.4	17
28	Robustness of Equations that Define Molecular Subtypes of Glioblastoma Tumors Based on Five Transcripts Measured by RT-PCR. OMICS A Journal of Integrative Biology, 2015, 19, 41-51.	1.0	2
29	Effect of acute hyperglycemia on moderately hypothermic GL261 mouse glioma monitored by T1-weighted DCE MRI. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2015, 28, 119-126.	1.1	0
30	Non-invasive grading of astrocytic tumours from the relative contents of myo-inositol and glycine measured by in vivo mrs. Journal of the Belgian Society of Radiology, 2015, 94, 319.	0.2	17
31	Molecular imaging coupled to pattern recognition distinguishes response to temozolomide in preclinical glioblastoma. NMR in Biomedicine, 2014, 27, 1333-1345.	1.6	21
32	Ex vivo assessment of polyol coated-iron oxide nanoparticles for MRI diagnosis applications: toxicological and MRI contrast enhancement effects. Journal of Nanoparticle Research, 2014, 16, 1.	0.8	18
33	A new ex vivo method to evaluate the performance of candidate MRI contrast agents: a proof-of-concept study. Journal of Nanobiotechnology, 2014, 12, 12.	4.2	16
34	DCE@urLAB: a dynamic contrast-enhanced MRI pharmacokinetic analysis tool for preclinical data. BMC Bioinformatics, 2013, 14, 316.	1.2	33
35	Strategies for annotation and curation of translational databases: the eTUMOUR project. Database: the Journal of Biological Databases and Curation, 2012, 2012, bas035-bas035.	1.4	17
36	Improving the classification of brain tumors in mice with perturbation enhanced (PE)-MRSI. Integrative Biology (United Kingdom), 2012, 4, 183-191.	0.6	17

#	Article	IF	Citations
37	Minimization of spectral pattern changes during HRMAS experiments at 37 degrees celsius by prior focused microwave irradiation. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2012, 25, 401-410.	1.1	9
38	Efficient Î³-amino-proline-derived cell penetrating peptideâ€“superparamagnetic iron oxide nanoparticle conjugates via aniline-catalyzed oxime chemistry as bimodal imaging nanoagents. Chemical Communications, 2012, 48, 5322.	2.2	21
39	In Vivo Magnetic Resonance Spectroscopic Imaging and Ex Vivo Quantitative Neuropathology by High Resolution Magic Angle Spinning Proton Magnetic Resonance Spectroscopy. Neuromethods, 2012, , 329-365.	0.2	3
40	Prospective diagnostic performance evaluation of singleâ€voxel ¹H MRS for typing and grading of brain tumours. NMR in Biomedicine, 2012, 25, 661-673.	1.6	55
41	Improving the classification of brain tumors in mice with perturbation enhanced (PE)-MRSI. BMC Proceedings, 2010, 4, .	1.8	0
42	Short-term temperature effect on the HRMAS spectra of human brain tumor biopsies and their pattern recognition analysis. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2010, 23, 203-215.	1.1	9
43	Development of a Predictor for Human Brain Tumors Based on Gene Expression Values Obtained from Two Types of Microarray Technologies. OMICS A Journal of Integrative Biology, 2010, 14, 157-164.	1.0	12
44	Multiprojectâ€“multicenter evaluation of automatic brain tumor classification by magnetic resonance spectroscopy. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2009, 22, 5-18.	1.1	126
45	In vivo proton magnetic resonance spectroscopy of intraventricular tumours of the brain. European Radiology, 2009, 19, 2049-2059.	2.3	43
46	Assignment of the 2.03 ppm resonance in in vivo 1H MRS of human brain tumour cystic fluid: contribution of macromolecules. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2004, 17, 36-46.	1.1	20